Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

@article{Rastetter2004RituximabER,
  title={Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.},
  author={William H. Rastetter and Arturo Molina and Christine A. White},
  journal={Annual review of medicine},
  year={2004},
  volume={55},
  pages={477-503}
}
Rituximab (Rituxan) is a human-mouse chimeric monoclonal antibody that targets the B-cell CD20 antigen and causes rapid and specific B-cell depletion. Rituximab was approved in the United States in 1997 to treat low-grade or follicular, relapsed or refractory, CD20-positive B-cell non-Hodgkin's lymphoma (NHL). Since then, further clinical experience with rituximab has been incorporated into the prescribing information, which now stipulates an extended eight-week schedule, treatment of patients… CONTINUE READING